Bone sarcoma: success through interdisciplinary collaboration

Stefanie Hecker-Nolting1,4
Ana Maia Ferreira2,4
Stefan S. Bielack1,3

Abstract

Purpose: Osteosarcoma and Ewing sarcoma are the most frequent malignant bone tumours of childhood and adolescence. This review summarizes the oncologist’s view of these diseases and their treatment.

Methods: A non-systematic literature review was performed, the personal impressions and experience of the authors is described.

Results: Local therapy and chemotherapy, each on their own, will not cure patients with malignant bone sarcomas. Together, they present a highly efficacious combination. While the most effective drugs were defined decades ago, progress since then has been limited. It is hoped that substances shown to be active in relapsed disease will be forwarded into even more efficacious frontline treatments. Good palliative therapy is necessary when cure is no longer an option.

Conclusion: Close interdisciplinary collaboration is the key to successful treatment of bone sarcomas in paediatric patients.

Introduction

Osteosarcoma and Ewing sarcoma are the classic example of what is feasible only by close interdisciplinary collaboration. The (orthopaedic) surgeon alone cannot cure the affected patient, neither can the radiotherapist. The (pediatric) oncologist alone cannot cure the patient. Together with other disciplines such as pathology, radiology, thoracic surgery and others, however, they can turn the majority of affected patients into long-term, disease-free survivors who are able to lead a productive life. This paper will review the essence of this collaboration and will highlight the oncologist’s role.

Epidemiology and natural disease course

High-grade osteosarcoma of bone is a typical malignancy of adolescents and young adults. Male children, adolescents and young adults are affected more frequently than female. The primary tumour typically arises in the metaphysis of a long bone, most frequently the femur. Metastases usually involve the lung, less frequently other bones, only rarely other sites. They are present in a minority of patients at diagnosis, but will arise in almost all with local therapy only.4 Rare variants may be less malignant and treatable by surgery alone. An exact diagnosis by an experienced bone sarcoma reference pathologist is essential.3 All Ewing sarcomas are fully malignant, there are no low-grade variants. This is also a typical disease of adolescence. About half of all cases involve the body trunk, half the extremities. Male children, adolescents and young adults are again affected slightly more often than female. Metastases involve the lungs and distant bones equally, other organs less commonly.4,5 Again, diagnosis by reference pathology centre is strongly recommended.3 Ewing sarcoma is characterized by specific genetic alterations, translocations involving the EWSR-gene with a member of the ETS-family, most often FLI1.6 Molecular biology should be a routine part of every workup for a suspected Ewing sarcoma. It may be the only chance to distinguish this diagnosis from other tumours such as CIC-DUX4, BCOR-CCNB3 or other, rarer translocations. The distinction between Ewing sarcoma and the so-called Ewing-like sarcomas is essential, as the different tumour types may also be treated differently.7
The strong tendency for metastases has major therapeutic implications for both bone cancers: even the most sophisticated operative procedure of the primary alone will not save the patient! Major improvements of the up to then dismal prognosis of both sarcomas occurred only some 45 years ago when adjuvant (postoperative) and a little later neoadjuvant (preoperative) multidrug chemotherapy was added to surgery. Multiple prospective trials and registries have then shown disease-free survival rates of some 50% to 80%, depending on the patients who were included.1,2,4,5

Local therapy: from the oncologist’s view

Surgical removal of the primary osteosarcoma and any primary metastases remains a prerequisite for cure in 2021. The type of surgery used does not affect cure rate if the principles of a ‘wide’ resection6 are followed. This means that the tumour and a surrounding, unviolated cuff of normal tissue must be removed en bloc. Metastases are operated using this same principle. The surgeon may be aided by the oncologist, as tumours devitalized by preoperative chemotherapy tend to have a lower local recurrence rate.7 If wide margins are not achieved, local recurrence and a dismal prognosis are heralded.8 Modern radiotherapy techniques such as proton therapy may save the occasional patient when complete surgery is not an option.9 However, complete surgery must remain the first choice in all cases.

In Ewing sarcoma, radiotherapy may also be very effective. Adequate surgery, however, seems to be even more efficacious,10 leading to a shift in preferences. Nowadays, operable Ewing sarcomas are usually operated, while radiotherapy remains a viable option for inoperable sites. The same surgical principles as for osteosarcoma must be followed. Radiotherapy may be added after surgery.14

The discussion about how large the cuff of normal tissue surrounding must be is ongoing for both sarcomas. Fascia probably present a certain barrier to tumour extension. It must be highlighted that everything must go in a correct manner, starting with the biopsy, as any operative errors will lead to local recurrences and often death.10,15

Chemotherapy: why, when, and how

Chemotherapy is always a part of curative therapy for high-grade osteosarcoma and for Ewing sarcoma. In osteosarcoma, four agents have emerged as the most efficacious: Doxorubicin (adriamycin), high-dose methotrexate, cisplatin and ifosfamide. Protocols using at least three of these were found clearly superior to others.16 Multiple other agents have been tested, none has gained universal acceptance. In Ewing sarcoma, doxorubicin, ifosfamide or cyclophosphamide, etoposide, vincristine and actinomycin D are heralded as the most efficacious.4,5

Doxorubicin was first introduced into therapy in the 1970s.17,18 It may be the most active agent of all.19 A major concern is its potential for cardiotoxicity. Attempts to reduce this life-threatening side effect include limiting its cumulative dose, avoiding high peak drug-levels, and coadministration of the cardioprotectant dexrazoxane.20 Analogues have so far not demonstrated equivalence.

High-dose methotrexate entered medical therapy at about the same time as doxorubicin.21 Ultra-high doses are required for its efficaciousness and extensive accompanying supportive measures are mandatory. Largely devoid of late effects, it carries the risk for a stop of renal elimination and ensuing severe acute toxicity. This can only be countered by high doses of the antidote, leucovorin and measures to hasten excretion of the drug. In recent years, glucarpidase (carboxypeptidase G2), an enzyme which cleaves methotrexate into less toxic metabolites, has been added to the therapeutic armamentarium for such cases.22

In osteosarcoma, cisplatin’s intra-arterial administration directly into the vessel nourishing the tumour was not shown more efficacious than administering it via the traditional intra-venous route.23 Important toxicities include renal impairment and hearing loss. The genetic make-up of an individual may influence this largely irreversible toxicity.24 Administration of the drug over a longer period of time in order to lower peak-levels may be beneficial.

Ifosfamide was the last active agent to be introduced against osteosarcoma and is also active against Ewing sarcoma.25 Its analogue’s cyclophosphamide’s activity seems to be somewhat lower and largely limited to Ewing sarcoma.26 Ifosfamide toxicities include haemorrhagic cystitis, making the concomitant administration of the uroprotector sodium-2-mercaptoethane sulfonate (Mesna) mandatory, and renal electrolyte wasting. The latter becomes more common with increasing cumulative ifosfamide doses.27,28

The epipodophyllotoxin etoposide (VP16) is a part of frontline therapy against Ewing sarcoma and part of some protocols for recurrent osteosarcoma. While other late effects are rare, it carries the risk of early secondary acute myeloid leukemias.29 The drug is, therefore, not given without some hesitation.

The vinca-alkaloid vincristine and the antitumour antibiotic actinomycin D are both associated with acute toxicities, but largely devoid of severe late effects. Both are active against Ewing sarcoma and may be combined with other agents.10 They must be administered strictly intravenously, as they are strong vesicants.

Whilst preoperative, neoadjuvant therapy is part of basically all modern treatment protocols in both sarcoma,2,4 it probably does not increase cure rates above those achievable with postoperative, adjuvant therapy.
alone. However, it allows time to prepare for optimal surgery and allows assessment of the histological response to the preoperative regimen. This response has emerged as one of the strongest prognostic factors in osteosarcoma and Ewing sarcoma. Unfortunately, attempts to improve the outcome of poor responders by postoperative treatment adaptations have proven completely unsuccessful in osteosarcoma. Most notably, the world’s largest ever osteosarcoma trial, EURAMOS-1, failed to show any effect of adding high-dose etoposide and ifosfamide to the poor response regimen.

In Ewing sarcoma, the situation is more complex and certain subgroups may benefit from postoperative alterations for poor responders. High-dose chemotherapy plus stem cell rescue benefitted patients with localized disease but a poor response to preoperative chemotherapy in the EURO-E.W.I.N.G.99 trial. Using a conventional backbone of vincristine, ifosfamide, doxorubicin and etoposide (VIDE), the trial showed the benefit of adding a single course of busulfan/melphalan high-dose treatment for poor responders. In the same EURO-E.W.I.N.G.99 study, patients with lung metastases did not benefit from high-dose chemotherapy compared with pulmonary irradiation.

The Children’s Oncology Group, representing North America’s paediatric oncologists, used a different backbone chemotherapy, vincristine, ifosfamide, doxorubicin and cyclophosphamide (VDC). The success rate of this regimen could be improved by adding ifosfamide and etoposide (VDC/IE). They improved the cure rate further by interval compression aided by granulocyte colony stimulating factor, but not by further dose-escalation. Regimens based on Europe’s VIDE and America’s interval-compressed VDC/IE were compared in the prospective EURO-E.W.I.N.G.2012 study. Interval compressed VDC/IE emerged as more efficacious and less toxic and is considered the new standard.

Over the decades, multiple additional trials have been performed by many institutions or cooperative groups. The interested reader is referred to recent reviews.

What to do in case of recurrence

Approximately 20% to 50% of bone sarcoma patients, depending on selection criteria, will develop recurrences. In osteosarcoma, these may be local or metastatic, with the lung being by far the most commonly affected organ, followed by distant bones. In Ewing sarcoma, the organs at risk are the lungs and bones at approximately even proportions, less frequently others.

The same surgical principles as described apply to recurrences, be they local or metastatic. Again, all sites of recurrent osteosarcoma must be removed with wide or radical margins to enable long-term survival. Only a small minority will become long-term survivors of recurrent Ewing sarcoma. Local therapy following the guidelines for primary disease plus a variety of systemic approaches may be attempted.

In recurrent osteosarcoma, the debate about whether to use second-line systemic therapy or to rely on surgery alone is still open. Most investigators agree that solitary recurrences arising more than three years after initial diagnosis can be treated by surgery alone. Other recurrences may benefit from second line chemotherapy, albeit to a much smaller degree than during primary treatment. The optimal drugs are yet to be well defined. Most oncologists would agree to administer any of the clearly efficacious drugs not given during primary treatment. Further options, some but not all supported by phase II trials, include high-dose ifosfamide, carboplatin/etoposide or gemcitabine/docetaxel.

In Ewing sarcoma, the optimal systemic treatment of relapse has also not been defined. A major step forward to filling this void is the ongoing pan-European rEECur study. There, various chemotherapy regimens are tested for their efficacy in a multi-arm, multi-step design. First results have shown gemcitabine/docetaxel, then irinotecan/temozolomide to be less efficacious than topotecan/cyclophosphamide or high-dose ifosfamide. The trial is ongoing and other arms may be added.

Multiple non-chemotherapeutic drugs have also been tested in phase II trials, most notably tyrosine-kinase inhibitors. A major hurdle in the testing of any new osteosarcoma agent – not true for Ewing sarcoma – is that the tumour’s osteoid matrix prevents shrinkage even when the agent in question kills all osteosarcoma cells. Hence, innovative ways to measure a drug’s efficaciousness must be sought and found. Methods used recently to try to define a drug’s activity include, for example, randomized comparisons of the time to progression. It remains to be seen if any of the investigated agents will be able to increase cure rates.

What to do when complete surgery and cure are no longer options

An osteosarcoma patient’s disease becomes palliative the moment that any lesion is no longer amenable to complete surgery. Extrapulmonary lesions become more and more frequent as the disease progresses, be it as metastases in their own right, by implantation during previous surgeries or as extrapulmonary extension of pulmonary lesions. In Ewing sarcoma, treatment can also become palliative at any time of disease progression. Palliative therapy usu-
Bone sarcoma: success through collaboration

Outlook into the future

Osteosarcoma and Ewing sarcoma remain incurable for surgeons (or radiotherapists) or oncologists alone, while the majority of affected young patients can be made free of disease if the disciplines work together throughout therapy. The past decades have seen major operative improvements, both related to tumour removal and to reconstruction. Unfortunately, medical therapy has been met with comparatively limited progress, despite numerous attempts to find more efficacious treatments. It is hoped that new, especially targeted drugs, added to standard chemotherapy will be able to break this stalemate. Close collaboration between surgical and non-surgical specialists will remain essential to achieve progress. Only then can the ultimate goal of bone sarcoma therapy be reached: one day, nobody should have to die from these cancers.

Received 11 June 2021, accepted 15 June 2021

COMPLIANCE WITH ETHICAL STANDARDS

FUNDING STATEMENT

The author or one or more of the authors have received or will receive benefits for personal or professional use from a commercial party related directly or indirectly to the subject of this article.

OA LICENCE TEXT

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) licence (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed.

ETHICAL STATEMENT

Ethical approval: This research involved a review of the pertinent literature only. No humans or animals were used. No Institutional Review Board/Ethics Committee was involved in this literature review.

Informed consent: There were no research subjects, hence no informed consent was obtained.

ICMJE CONFLICT OF INTEREST STATEMENT

This work was supported by Förderkreis krebskranke Kinder Stuttgart e. V. Stefanie Hecker-Nolting reports grants from Förderkreis krebskranke Kinder Stuttgart e.V. during the conduct of the study; grants from EISAI, outside the submitted work. Ana Maia Ferreira declares that she has no conflict of interest. Stefan S. Bielack reports having acted as consultant and/or advisory board member for Bayer Healthcare, Boehringer Ingelheim, Hoffmann-La Roche, Ipsen, Eli Lilly, and Sensorion.

AUTHOR CONTRIBUTIONS

SHN: Writing and completion of the manuscript, Read and approved the final version for submission

AMF: Writing and completion of the manuscript, Read and approved the final version for submission

S SB: Writing and completion of the manuscript, Read and approved the final version for submission

REFERENCES

1. Grohar PJ, Janeway KA, Mase LD, Schiffman JD. Advances in the treatment of Pediatric Bone Sarcomas. Am Soc Clin Oncol Educ Book 2017;37:725-735.

2. Bielack S, Cable MG, Gorlick R, et al. Osteosarcoma - approach to therapy. In: Arndt CAS, ed. Sarcomas of bone and soft tissues in children and adolescents. Pediatric oncology. Cham: Springer, 2021.

3. Casali PG, Bielack S, Abecassis N, et al. Bone sarcomas: ESMO/ParCor-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29:79-95.

4. Pappo AS, Dirksen U. Rhabdomyosarcoma, Ewing sarcoma, and other round cell sarcomas. J Clin Oncol 2018;36:168-179.

5. Hesla AC, Papakonstantinou A, Tsagkozis P. Current status of management and outcome for patients with Ewing sarcoma. Cancers (Basel) 2021;13:1202.

6. Grünewald TGP, Cidre-Aranaz F, Surdez D, et al. Ewing sarcoma. Nat Rev Dis Primers 2018;4:5.
7. Kinnaman MD, Zhu C, Weiser DA, et al. Survey of paediatric oncologists and pathologists regarding their views and experiences with variant translocations in Ewing and Ewing-like sarcoma. a report of the Children's Oncology Group. Sarcoma 2020;34:8549.

8. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980;153:106-120.

9. Picci P, Sangiorgi L, Rougraff BT, et al. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 1994;12:2699-2705.

10. Andreou D, Bielack SS, Carrie D, et al. The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. Ann Oncol 2011;22:1228-1235.

11. Ciernik IF, Niemierko A, Harmon DC, et al. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer 2011;117:4522-4530.

12. Seidensaal K, Mattke M, Haufe S, et al. The role of combined ion-beam radiotherapy (CIBRT) with protons and carbon ions in a multimodal treatment strategy of inoperable osteosarcoma. Radiother Oncol 2021;159:8-16.

13. Whelan J, Hackshaw A, McTiernan A, et al. Survival is influenced by approaches to local treatment of Ewing sarcoma within an international randomised controlled trial: analysis of EICESS-92. Clin Sarcoma Res 2018;8:6.

14. Foulon S, Brennan B, Gaspar N, et al. Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group. Eur J Cancer 2016;61:128-136.

15. Andreou D, Ranft A, Gosheger G, et al. Which factors are associated with local control and survival of patients with localized pelvic Ewing’s sarcoma? A retrospective analysis of data from the Euro-E.W.I.N.G trial. Clin Orthop Relat Res 2020;478:290-302.

16. Anninga JK, Gelderblom H, Fiocco M, et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer 2011;47:2483-2495.

17. Wang JJ, Cortes E, Sinks LF, Holland JF. Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease. Cancer 1971;28:837-843.

18. Oldham RK, Pomeroy TC. Treatment of Ewing’s sarcoma with adriamycin (NSC-123127). Cancer Chemother Rep 1972;56:635-639.

19. Smith MA, Ungerleider RS, Horowitz ME, Simon R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing’s sarcoma. J Natl Cancer Inst 1991;83:1640-1647.

20. Robinson EL, Azodi M, Heymans S, Heggermont W. Anthracycline-related heart failure: certain knowledge and open questions: where do we stand with chemotherapy-induced cardiotoxicity? Curr Heart Fail Rep 2020;17:357-364.

21. Jaffe N. Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer 1972;30:1627-1631.

22. Widemann BC, Schwartz S, Jayaprakash N, et al. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy. Pharmacotherapy 2014;34:427-439.

23. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the cooperative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998;9:893-899.

24. Langer T, Clemens E, Broer L, et al. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: results of the European PanCareLIFE cohort study. Eur J Cancer 2020;138:212-224.

25. Meyers PA. Systemic therapy for osteosarcoma and Ewing sarcoma. Am Soc Clin Oncol Educ Book 2015;35:e664-e667.

26. Paulussen M, Craft AW, Lewis I, et al. Results of the EICESS-92 Study: two randomized trials of Ewing’s sarcoma treatment – cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 2008;26:4385-4393.

27. Stöhr W, Paulides M, Bielack S, et al. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System. Pediatr Blood Cancer 2007;48:447-452.

28. Gangireddy M, Nookala V. Ifosfamide. StatPearls. Treasure Island (FL): StatPearls Publishing, 2021. https://www.ncbi.nlm.nih.gov/books/NBK542169/ [Date last accessed 27 May 2021].

29. Reyhanoglu G, Tadi P. Etoposide. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2021. https://www.ncbi.nlm.nih.gov/books/NBK57864/ [Date last accessed 27 May 2021].

30. Gaspar N, Hawkins DS, Dirksen U, et al. Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol 2015;33:3036-3046.

31. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776-790.

32. Bosma SE, Rueten-Budde AJ, Lancia C, et al. Individual risk evaluation for local recurrence and distant metastasis in Ewing sarcoma: a multistate model: a multistate model for Ewing sarcoma. Pediatr Blood Cancer 2019;66:627943.

33. Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol 2016;17:1396-1408.

34. Whelan J, Le Deley MC, Dirksen U, et al. High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk Ewing sarcoma: results of Euro-E.W.I.N.G-99 and Ewing-2008. J Clin Oncol 2018;36:JCO2018782516.

35. Dirksen U, Brennan B, Le Deley MC, et al. High-dose chemotherapy compared with standard chemotherapy and lung radiation in Ewing sarcoma with pulmonary metastases: results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. J Clin Oncol 2019;37:3192-3202.

36. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694-701.

37. Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol 2012;30:4148-4154.
38. Granowetter L, Womer R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children’s Oncology Group Study. J Clin Oncol 2009;27:2536-2541.

39. Brennan B, Kirton L, Marec-Berard P, et al. Comparison of two chemotherapy regimens in Ewing sarcoma (ES): overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012). J Clin Oncol 2020;38:15_suppl; abstr T1500).

40. Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther 2018;18:39-50.

41. Kempf-Bielack B, Bielack SS, Jürgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005;23:559-568.

42. Durer S, Shaikh H. Ewing Sarcoma. In: StatPearls. Treasure Island, FL: StatPearls Publishing;2021. https://www.ncbi.nlm.nih.gov/books/NBK559183/[Date last accessed 27 May 2021]

43. Bielack SS, Kempf-Bielack B, Branscheid D, et al. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol 2009;27:557-565.

44. Felix A, Berlanga P, Toulmonde M, et al. Systematic review of phase-I/II trials enrolling refractory and recurrent Ewing sarcoma: actual knowledge and future directions to optimize the research. Cancer Med 2021;10:1589-1604.

45. McCabe MG, Moroz V, Khan M, et al. Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma. J Clin Oncol 2019;37:11007.

46. McCabe MG, Kirton L, Khan M, et al. Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). J Clin Oncol 2020;38(suppl):11502.

47. Omer N, Le Deley MC, Piperno-Neumann S, et al. Phase-II trials in osteosarcoma recurrences: a systematic review of past experience. Eur J Cancer 2017;75:98-108.

48. Gazouli I, Kyriazoglou A, Kotsantis I, et al. Systematic review of recurrent osteosarcoma systemic therapy. Cancers (Basel) 2021;13:1757.

49. Benjamin RS. Osteosarcoma: better treatment through better trial design. Lancet Oncol 2015;16:12-13.

50. O’Brien T, Chirstrup LL, Drewes AM, et al. European Pain Federation position paper on appropriate opioid use in chronic pain management. Eur J Pain 2017;21:3-19.

51. Chen EL, Yoo CH, Gutkin PM, et al. Outcomes for pediatric patients with osteosarcoma treated with palliative radiotherapy. Pediatr Blood Cancer 2020;67:27967.

52. Sansom-Daly UM, Wakefield CE, Patterson P, et al. End-of-life communication needs for adolescents and young adults with cancer: recommendations for research and practice. J Adolesc Young Adult Oncol 2020;9:157-165.